These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24969380)

  • 41. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam.
    Currier GW; Chou JC; Feifel D; Bossie CA; Turkoz I; Mahmoud RA; Gharabawi GM
    J Clin Psychiatry; 2004 Mar; 65(3):386-94. PubMed ID: 15096079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The use of reminyl (galantamine) in the treatment of probable vascular dementia].
    Mokhova OI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(9):77-9. PubMed ID: 19911468
    [No Abstract]   [Full Text] [Related]  

  • 43. Galantamine treatment of vascular dementia: a randomized trial.
    Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
    Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Agitation in nursing home residents with dementia (VIDEANT trial): effects of a cluster-randomized, controlled, guideline implementation trial.
    Rapp MA; Mell T; Majic T; Treusch Y; Nordheim J; Niemann-Mirmehdi M; Gutzmann H; Heinz A
    J Am Med Dir Assoc; 2013 Sep; 14(9):690-5. PubMed ID: 23827658
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.
    Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
    Neuropharmacology; 2007 Sep; 53(3):379-89. PubMed ID: 17632185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Don't use antipsychotics routinely to treat agitation and aggression in people with dementia.
    Corbett A; Burns A; Ballard C
    BMJ; 2014 Nov; 349():g6420. PubMed ID: 25368388
    [No Abstract]   [Full Text] [Related]  

  • 47. [Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients].
    Kurz A; Delius-Stute H; Rettig K; Schwalen S
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():89-95. PubMed ID: 15490773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice.
    Kurz A; Schwalen S S; Schmitt A
    Int Psychogeriatr; 2005 Dec; 17(4):605-16. PubMed ID: 16185378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model.
    Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
    Neuropharmacology; 2007 Mar; 52(4):1179-87. PubMed ID: 17313962
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.
    Burns A; Bernabei R; Bullock R; Cruz Jentoft AJ; Frölich L; Hock C; Raivio M; Triau E; Vandewoude M; Wimo A; Came E; Van Baelen B; Hammond GL; van Oene JC; Schwalen S
    Lancet Neurol; 2009 Jan; 8(1):39-47. PubMed ID: 19042161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Beneficial effects of perospirone on aggressive behavior associated with dementia.
    Sato S; Mizukami K; Moro K; Tanaka Y; Asada T
    Psychiatry Clin Neurosci; 2006 Feb; 60(1):106-9. PubMed ID: 16472367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography.
    Holmgren S; Andersson T; Berglund A; Aarsland D; Cummings J; Freund-Levi Y
    J Neuropsychiatry Clin Neurosci; 2022; 34(3):214-223. PubMed ID: 35306829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease.
    Monsch AU; Giannakopoulos P;
    Curr Med Res Opin; 2004 Jun; 20(6):931-8. PubMed ID: 15200752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients.
    Chan WC; Lam LC; Choy CN; Leung VP; Li SW; Chiu HF
    Int J Geriatr Psychiatry; 2001 Dec; 16(12):1156-62. PubMed ID: 11748775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis.
    Lin YT; Hwang TJ; Shan JC; Chiang HL; Sheu YH; Hwu HG
    J Formos Med Assoc; 2015 Feb; 114(2):147-53. PubMed ID: 25678176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment options: the latest evidence with galantamine (Reminyl).
    Erkinjuntti T
    J Neurol Sci; 2002 Nov; 203-204():125-30. PubMed ID: 12417370
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-acting injectable risperidone for control of agitation in dementia.
    Yumru M; Eren Ozen M; Savas HA; Selek S
    J Clin Psychiatry; 2006 Oct; 67(10):1651-2. PubMed ID: 17107263
    [No Abstract]   [Full Text] [Related]  

  • 59. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial.
    Ghaleiha A; Ghyasvand M; Mohammadi MR; Farokhnia M; Yadegari N; Tabrizi M; Hajiaghaee R; Yekehtaz H; Akhondzadeh S
    J Psychopharmacol; 2014 Jul; 28(7):677-85. PubMed ID: 24132248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Emelin AIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):25-33. PubMed ID: 18427456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.